The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2021 | Improving our understanding of MDS for better disease management
Sandra Kurtin, PhD, ACNP-BC, AOCN, University of Arizona, Tucson, AZ, highlights the importance of understanding the molecular underpinnings of myelodysplastic syndromes (MDS) and other myeloid malignancies, such as myeloproliferative neoplasms and acute myeloid leukemia, as well as commenting on their significance in the design of new treatments. Dr Kurtin also explains how the bone marrow and its microenvironment might have a predictive value. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
